The therapeutic efficacy of drugs is dependent upon the ability of a drug to reach its target,
and drug penetration into tumors is limited by abnormal vasculature and high interstitial …

Surface functionalization of liposomes can play a key role in overcoming the current
limitations of nanocarriers to treat solid tumors, ie, biological barriers and physiological …

Hydroxyapatite nanoparticles (HAP NPs) are host materials and can be modified with
various substrates and dopants. Among them, rare earth (RE) ions doped HAP NPs have …

Most cancer drugs are designed to interfere with one or more events in cell proliferation or
survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer …

The burden of cancer is continuously increasing, and is rapidly becoming a global
pandemic. The first liposomal encapsulated anticancer drug which received clinical …

Effective treatment for glioblastoma (GBM) is limited by the presence of the blood–brain
barrier (BBB) and rapid resistance to single agent therapies. To address these issues, we …

Extracellular vesicles (EVs) are increasingly being recognized as candidate drug delivery
systems due to their ability to functionally transfer biological cargo between cells. However …

Recent advances in nanoparticle technology have enabled the fabrication of nanoparticle
classes with unique sizes, shapes and materials, which in turn has facilitated major …

Effective non-invasive treatment of neurological diseases is often limited by the poor access
of therapeutic agents into the central nervous system (CNS). The majority of drugs and …

Liposomal delivery systems have significantly enhanced the efficacy and safety of
chemotherapeutic agents compared to free (non-liposomal) formulations. Liposomes are …